Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024
May 10, 2024 at 04:15 am EDT
Share
Dr. Lal PathLabs Limited announced that at its board meeting held on May 10, 2024, approved the recommendation of final dividend of INR 6 per equity share (at 60% on a face value of INR 10 each) for the financial year ended March 31, 2024 subject To Approve the Shareholders at upcoming Annual General Meeting (AGM) of the company. The record date for the purpose of payment of final dividend shall be June 10, 2024.
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.